WO2010018837A3 - 蛋白質架橋阻害剤 - Google Patents

蛋白質架橋阻害剤 Download PDF

Info

Publication number
WO2010018837A3
WO2010018837A3 PCT/JP2009/064206 JP2009064206W WO2010018837A3 WO 2010018837 A3 WO2010018837 A3 WO 2010018837A3 JP 2009064206 W JP2009064206 W JP 2009064206W WO 2010018837 A3 WO2010018837 A3 WO 2010018837A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein cross
linking inhibitor
linking
inhibitor
symbols
Prior art date
Application number
PCT/JP2009/064206
Other languages
English (en)
French (fr)
Other versions
WO2010018837A2 (ja
Inventor
御子柴　克彦
信行 貫名
庄一郎 尾崎
耕造 濱田
純一 後藤
商信 鈴木
悦子 戎井
明子 寺内
Original Assignee
独立行政法人科学技術振興機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 独立行政法人科学技術振興機構 filed Critical 独立行政法人科学技術振興機構
Priority to JP2010524739A priority Critical patent/JP5606913B2/ja
Priority to US13/058,647 priority patent/US8853424B2/en
Publication of WO2010018837A2 publication Critical patent/WO2010018837A2/ja
Publication of WO2010018837A3 publication Critical patent/WO2010018837A3/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明は、下記の一般式（１）～（１３）のいずれかの式によって表される化合物又はその薬学的に許容可能な塩を含む、蛋白質架橋阻害剤を提供する。 （１）Ｒ３－［－Ｘ－Ｂ（ＺＲ１）－Ｙ－Ｂ（ＺＲ２）－Ｗ－］ｎ－Ｒ４、 （２）Ｒ３－［－Ｘ－Ｂ（ＺＲ１）－Ｙ－］ｎ－Ｒ４、 （３）Ｒ３－［－Ｂ（ＺＲ１）－Ｙ－Ｂ（ＺＲ２）－Ｗ－］ｎ－Ｒ４、 （４）Ｒ３－［－Ｘ－Ｂ（ＺＲ１）－］ｎ－Ｒ４、 （５）Ｒ３－［－Ｂ（ＺＲ２）－Ｗ－］ｎ－Ｒ４、 （６）Ｒ３－Ｘ－Ｂ（ＺＲ１）－Ｔ［Ｂ（ＺＲ２）－Ｗ－Ｒ４］２、 （７）Ｒ３－Ｂ（ＯＨ）２、 （８）Ｒ３－Ｂ（ＺＲ１）－Ｘ－Ｂ（ＺＲ２）－Ｒ４、 （９）Ｒ３－Ｂ(Ｒ１)－Ｏ－Ｂ（Ｒ２）－Ｒ４、 （１０）Ｒ３－［－Ｘ－Ｂ（ＺＲ１）－Ｙ－Ｂ（ＺＲ２）－］ｎ－Ｒ４、 （１１）Ｒ３－［－Ｘ－Ｂ（ＺＲ１）－Ｙ－Ｂ（ＺＲ２）－Ｗ－Ｑ－］ｎ－Ｒ４、 （１２）Ｒ３－［－Ｐ－Ｘ－Ｂ（ＺＲ１）－Ｙ－Ｂ（ＺＲ２）－Ｗ－］ｎ－Ｒ４、 （１３）[Ｒ３－Ｘ－Ｂ（ＺＲ１）－Ｙ]２Ｂ（ＺＲ２）、 〔式中、各記号は明細書中の定義と同義である。〕
PCT/JP2009/064206 2008-08-11 2009-08-11 蛋白質架橋阻害剤 WO2010018837A2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2010524739A JP5606913B2 (ja) 2008-08-11 2009-08-11 蛋白質架橋阻害剤
US13/058,647 US8853424B2 (en) 2008-08-11 2009-08-11 Protein cross-linking inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008207315 2008-08-11
JP2008-207315 2008-08-11

Publications (2)

Publication Number Publication Date
WO2010018837A2 WO2010018837A2 (ja) 2010-02-18
WO2010018837A3 true WO2010018837A3 (ja) 2010-04-15

Family

ID=41669420

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2009/064206 WO2010018837A2 (ja) 2008-08-11 2009-08-11 蛋白質架橋阻害剤
PCT/JP2009/064205 WO2010018836A2 (ja) 2008-08-11 2009-08-11 ポリグルタミン凝集阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/064205 WO2010018836A2 (ja) 2008-08-11 2009-08-11 ポリグルタミン凝集阻害剤

Country Status (3)

Country Link
US (1) US8853424B2 (ja)
JP (1) JP5606913B2 (ja)
WO (2) WO2010018837A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973835B2 (en) * 2017-03-09 2021-04-13 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
CN112011090A (zh) * 2020-09-09 2020-12-01 烟台融晟新材料有限公司 一种po膜用硼酸酯类内添界面接合剂及外涂液的改性剂

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040859A1 (en) * 1996-04-26 1997-11-06 President And Fellows Of Harvard College Bridge-substituted tropanes and uses
WO2003033002A1 (fr) * 2001-10-11 2003-04-24 Ono Pharmaceutical Co Inhibiteurs de l'augmentation de la concentration du calcium intracellulaire
JP2004524281A (ja) * 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
WO2006074419A2 (en) * 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
WO2007056341A1 (en) * 2005-11-08 2007-05-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2007061074A1 (ja) * 2005-11-25 2007-05-31 Japan Science And Technology Agency 新規ビスホウ素化合物
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007125351A1 (en) * 2006-04-27 2007-11-08 Senexis Limited Pyrimidine derivatives for the treatment of amyloid-related diseases
WO2007146965A2 (en) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
JP2008502694A (ja) * 2004-06-14 2008-01-31 アナコール ファーマシューティカルズ，インコーポレイテッド ボリン酸錯体の抗ウイルス使用
JP2008502702A (ja) * 2004-06-14 2008-01-31 アナコール ファーマシューティカルズ，インコーポレイテッド ボリン酸複合体の抗寄生虫的使用
JP2008502696A (ja) * 2004-06-14 2008-01-31 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有化合物およびその使用方法
WO2008055068A2 (en) * 2006-10-28 2008-05-08 Methylgene Inc. Inhibitors of histone deacetylase
JP2009184988A (ja) * 2008-02-07 2009-08-20 Institute Of Physical & Chemical Research 新規ホウ素化合物及びそれを含む細胞内カルシウム濃度調節剤又は医薬組成物

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040859A1 (en) * 1996-04-26 1997-11-06 President And Fellows Of Harvard College Bridge-substituted tropanes and uses
JP2004524281A (ja) * 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
WO2003033002A1 (fr) * 2001-10-11 2003-04-24 Ono Pharmaceutical Co Inhibiteurs de l'augmentation de la concentration du calcium intracellulaire
JP2008502694A (ja) * 2004-06-14 2008-01-31 アナコール ファーマシューティカルズ，インコーポレイテッド ボリン酸錯体の抗ウイルス使用
JP2008502696A (ja) * 2004-06-14 2008-01-31 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有化合物およびその使用方法
JP2008502702A (ja) * 2004-06-14 2008-01-31 アナコール ファーマシューティカルズ，インコーポレイテッド ボリン酸複合体の抗寄生虫的使用
WO2006074419A2 (en) * 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
WO2007056341A1 (en) * 2005-11-08 2007-05-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2007061074A1 (ja) * 2005-11-25 2007-05-31 Japan Science And Technology Agency 新規ビスホウ素化合物
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007125351A1 (en) * 2006-04-27 2007-11-08 Senexis Limited Pyrimidine derivatives for the treatment of amyloid-related diseases
WO2007146965A2 (en) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
WO2008055068A2 (en) * 2006-10-28 2008-05-08 Methylgene Inc. Inhibitors of histone deacetylase
JP2009184988A (ja) * 2008-02-07 2009-08-20 Institute Of Physical & Chemical Research 新規ホウ素化合物及びそれを含む細胞内カルシウム濃度調節剤又は医薬組成物

Also Published As

Publication number Publication date
WO2010018837A2 (ja) 2010-02-18
JP5606913B2 (ja) 2014-10-15
WO2010018836A2 (ja) 2010-02-18
WO2010018836A3 (ja) 2010-04-15
US20110212919A1 (en) 2011-09-01
US8853424B2 (en) 2014-10-07
JPWO2010018837A1 (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
WO2005094329A3 (en) Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
WO2008019395A3 (en) Compounds for improving learning and memory
EP1889842A4 (en) HETEROCYCLIC CONNECTION
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2009093028A3 (en) Polychromic substances and their use
WO2007061923A3 (en) Glucokinase activators
WO2007003934A3 (en) 17beta-hydr0xyster0id dehydrogenase type 3 (17beta-hsd3 ) inhibitors
EP2492264A3 (en) Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
AU2005297984A1 (en) Benzene compound having 2 or more substituents
GB0521508D0 (en) Organic compounds
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2006041631A3 (en) Novel cyclosporin alkynes and their utility as pharmaceutical agents
WO2005058888A3 (en) Oxazolidinone-quinolone hybrid antibiotics
WO2008047951A3 (en) An alzheimer' s disease progression inhibitor containing heterocyclic compound
WO2008117575A1 (ja) 防水シート
IS7795A (is) Pyrrólafleiður sem efnasambönd gegn sveppagerlum
WO2010021934A3 (en) Azaindole inhibitors of iap
NO20084543L (no) Benzimidazolderivater
WO2007058568A3 (fr) Sels et melanges d'acide 9-oxoacridine-10-acetique et de 1-alkylamino-1-desoxypolyols, compositions pharmaceutiques les contenant, et methodes de traitement associees
WO2007025089A3 (en) Triazole compounds and methods of making and using the same
WO2006078984A3 (en) Uses of methylphenidate derivatives
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09806728

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010524739

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13058647

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09806728

Country of ref document: EP

Kind code of ref document: A2